Nuvilex (PMCB) Competitors $1.02 +0.01 (+0.99%) Closing price 03:57 PM EasternExtended Trading$1.01 -0.01 (-0.49%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. KZR, PASG, FBLG, MIRA, XCUR, ENLV, MBRX, PMN, LIXT, and QTTBShould you be buying Nuvilex stock or one of its competitors? The main competitors of Nuvilex include Kezar Life Sciences (KZR), Passage Bio (PASG), FibroBiologics (FBLG), MIRA Pharmaceuticals (MIRA), Exicure (XCUR), Enlivex Therapeutics (ENLV), Moleculin Biotech (MBRX), Promis Neurosciences (PMN), Lixte Biotechnology (LIXT), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Nuvilex vs. Its Competitors Kezar Life Sciences Passage Bio FibroBiologics MIRA Pharmaceuticals Exicure Enlivex Therapeutics Moleculin Biotech Promis Neurosciences Lixte Biotechnology Q32 Bio Kezar Life Sciences (NASDAQ:KZR) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Is KZR or PMCB more profitable? Nuvilex's return on equity of -6.41% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -63.51% -52.13% Nuvilex N/A -6.41%-5.77% Do analysts rate KZR or PMCB? Kezar Life Sciences presently has a consensus target price of $9.00, suggesting a potential upside of 117.92%. Given Kezar Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kezar Life Sciences is more favorable than Nuvilex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor KZR or PMCB? In the previous week, Kezar Life Sciences' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score. Company Overall Sentiment Kezar Life Sciences Neutral Nuvilex Neutral Which has more volatility and risk, KZR or PMCB? Kezar Life Sciences has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Nuvilex has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Which has stronger earnings & valuation, KZR or PMCB? Nuvilex has lower revenue, but higher earnings than Kezar Life Sciences. Nuvilex is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M4.32-$83.74M-$9.69-0.43NuvilexN/AN/A$30.66M-$0.54-1.89 Do institutionals & insiders have more ownership in KZR or PMCB? 67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 10.4% of Kezar Life Sciences shares are owned by insiders. Comparatively, 10.2% of Nuvilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryKezar Life Sciences beats Nuvilex on 8 of the 12 factors compared between the two stocks. Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricNuvilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.86M$2.63B$6.11B$10.56BDividend YieldN/A56.71%5.69%4.75%P/E Ratio-1.8923.6985.4827.60Price / SalesN/A807.31624.19239.62Price / CashN/A173.2337.9261.55Price / Book0.135.5313.136.76Net Income$30.66M$32.78M$3.30B$275.88M7 Day Performance4.10%6.99%5.29%3.72%1 Month Performance-9.73%14.03%9.94%10.22%1 Year Performance-42.05%0.78%87.78%35.86% Nuvilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBNuvilex0.3156 of 5 stars$1.02+1.0%N/A-42.6%$6.86MN/A-1.894Analyst ForecastShort Interest ↑Gap UpKZRKezar Life Sciences3.5592 of 5 stars$3.90+8.6%$9.00+130.8%-50.1%$26.29M$7M-0.4060Analyst ForecastHigh Trading VolumePASGPassage Bio3.2981 of 5 stars$8.03-1.4%$75.67+842.3%-33.9%$25.88MN/A-0.44130Positive NewsAnalyst ForecastFBLGFibroBiologics1.9091 of 5 stars$0.55-10.8%$12.67+2,219.1%-82.3%$25.64MN/A-1.5210Analyst ForecastGap UpHigh Trading VolumeMIRAMIRA Pharmaceuticals0.5453 of 5 stars$1.36+2.3%N/A+17.0%$25.36MN/A-2.782Analyst ForecastXCURExicure1.7062 of 5 stars$4.09+4.9%N/A+52.8%$24.64M$500K-1.0550Analyst ForecastGap UpENLVEnlivex Therapeutics2.1604 of 5 stars$1.04+3.0%$10.00+861.5%-26.1%$24.54MN/A-1.7970Analyst ForecastMBRXMoleculin Biotech3.0042 of 5 stars$0.53+8.9%$4.00+654.7%-80.7%$24.10MN/A0.0020Analyst ForecastPMNPromis Neurosciences3.3456 of 5 stars$0.43-3.4%$4.33+919.6%-50.8%$23.68MN/A-2.025News CoveragePositive NewsAnalyst ForecastGap UpLIXTLixte BiotechnologyN/A$5.03-3.1%N/A+173.1%$23.67MN/A-3.904Analyst ForecastQTTBQ32 Bio2.8941 of 5 stars$1.98+2.1%$12.17+514.5%-94.2%$23.66M$1.16M-0.4639Gap Up Related Companies and Tools Related Companies KZR Competitors PASG Competitors FBLG Competitors MIRA Competitors XCUR Competitors ENLV Competitors MBRX Competitors PMN Competitors LIXT Competitors QTTB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersMelt-up warning America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
